ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VERA Vera Therapeutics Inc

37.99
1.04 (2.81%)
May 31 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 916,861
Bid Price 37.99
Ask Price 40.00
News -
Day High 38.40

Low
7.73

52 Week Range

High
50.78

Day Low 37.05
Company Name Stock Ticker Symbol Market Type
Vera Therapeutics Inc VERA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
1.04 2.81% 37.99 19:26:49
Open Price Low Price High Price Close Price Prev Close
37.62 37.05 38.40 37.99 36.95
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
11,024 916,861 $ 37.92 $ 34,768,627 - 7.73 - 50.78
Last Trade Time Type Quantity Stock Price Currency
19:38:08 3 $ 39.09 USD

Vera Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.69B 44.43M - 0 -95.99M -2.16 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Vera Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No VERA Message Board. Create One! See More Posts on VERA Message Board See More Message Board Posts

Historical VERA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week37.3139.3935.9137.08857,5580.681.82%
1 Month44.9648.5135.9140.59705,419-6.97-15.50%
3 Months44.1350.6535.85542.05935,734-6.14-13.91%
6 Months13.7850.7813.0735.601,043,97424.21175.69%
1 Year8.0050.787.7327.31849,21229.99374.88%
3 Years17.2550.785.2022.19418,00020.74120.23%
5 Years11.4150.785.2022.17414,02226.58232.95%

Vera Therapeutics Description

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.